PRTODAY / NewswireToday Free press release distribution service network

More news: Research
Written by / Agency / Source: IPSEN Group

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IPSEN and EpiVax Collaborate to Produce Next Generation Botulinum Toxins - Ipsen and EpiVax, Inc. (EpiVax) announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics -
IPSEN and EpiVax Collaborate to Produce Next Generation Botulinum Toxins


NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2015/10/26 - Ipsen and EpiVax, Inc. (EpiVax) announced that they have completed a collaborative project that provides a novel approach for creating next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics - Euronext: IPN; ADR: IPSEY

Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Ipsen is actively developing an innovative platform of novel neurotoxin derived therapeutics, including TSI, that is opening up new therapeutic opportunities to address various medical conditions with unmet need.

EpiVax will move the program forward, continuing potential product development for clinical use in neuromuscular health and aesthetic treatments. EpiVax will present the results of the research program so far conducted at the upcoming IBRCC 2015 conference on botulinum neurotoxins, in Frederick Maryland. EpiVax applied its proprietary T cell epitope modification technology “ISPRI” to generate an engineered BoNT sequence. This platform program employs two key technologies developed and perfected by EpiVax: deimmunization and tolerization.

Claude Bertrand, EVP Research & Development and Chief Scientific Officer of Ipsen stated: “Ipsen is pleased to have had a partnership with the US company EpiVax. This work is part of Ipsen’s commitment to apply modern protein engineering and recombinant protein expression to enable development of novel and improved botulinum neurotoxin products for increased therapeutic utility and patient care”.

Anne De Groot, CEO of EpiVax, commented: “The global biologics market is large, totaling nearly $234 billion in 2014 and expected to reach $386 billion1 by the end of 2019. This “stealth BoNT” program illustrates the potential to develop an entirely new product line of biologics. It capitalizes on technological advances and promises to bring better drugs, with defined mechanisms of action and well-known safety and efficacy profiles, to market.”

About Ipsen
Ipsen ( is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion ($1.4b) in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 40 countries. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Ipsen’s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors.

Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to €187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY.

About EpiVax
EpiVax, Inc. ( is a privately-held biotechnology company based in Providence, Rhode Island that is focused on the development of biologic products and vaccines for human and animal diseases. EpiVax provides access to its proprietary toolkits “ISPRI” and “iVAX” to most major pharmaceutical companies worldwide, and has developed proprietary tolerizing technology (Tregitopes). Led by Dr. Anne S. De Groot, M.D., immunologist and Bill Martin, architect of the ISPRI and iVAX immunoinformatics platforms, EpiVax has enjoyed success in the fields of immunology and bioinformatics. CEO De Groot was recently named one of the 50 most influential persons in the field of vaccines.

Ipsen Forward Looking Statements
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2014 Registration Document available on its website.

Media: Brigitte Le Guennec - Corporate External Communication Manager
T: +33(0)1 58 33 51 17 / F: +33(0)1 58 33 50 58
E: brigitte.le.guennec[.]

Financial Community: Stéphane Durant des Aulnois - VP Investor Relations
T: +33(0)1 58 33 60 09 / F: +33(0)1 58 33 50 63
E: stephane.durant.des.aulnois[.]

Côme de La Tour du Pin - Investor Relations Manager
T: +33(0)1 58 33 53 31 / F: +33(0)1 58 33 50 63

EpiVax: Anne S. De Groot MD - Chief Executive Officer
T: 401-272-1213 / M: 401-952-4227
E: AnnieD[.]

Assistant: Kelsey Hazelwood
T: 401-272-2123 - E: KHazelwood[.]

Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: IPSEN Group


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!

IPSEN and EpiVax Collaborate to Produce Next Generation Botulinum Toxins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

IPSEN | EpiVax, Inc.
Publisher Contact: Didier Véron - 
+33(0)1 58 33 51 16 didier.veron[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IPSEN Group securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From IPSEN Group / Company Profile

Read Research Most Recent Related Newswires:

DSM Launches ForTii® Ace Next Generation High Performance Polyamides
DSM Launches New Cultures to Reduce Cheese Ripening Time
DSM Launches New 3C Technology to Reinvigorate Omega-3 Supplements Category
DSM to Highlight its Health and Indulgence Solutions for Baked Goods At IBIE
DSM Welcomes EU Novel Foods Approval for Heart Health Antioxidant
DSM Dyneema Successfully Defends Key Patent Against Competitor Challenge
DSM Expands its Automotive Electronics Portfolio with High-flow Akulon PA66
BD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions
BD Announces New Software Release for Pyxis Enterprise Solution
DSM Opens its Asia Pacific Personal Care Technical & Application Center in Shanghai
IBM Research Opens in South Africa - Cognitive Computing and the IoT help Track Diseases and Forecast Air Quality
BD Cited as Infusion Pump EMR Integration Leader in Klas Report
DSM to Launch A New Uralac® EasyCure Low Bake/fast Cure Matte Architectural HAA Powder Coating Resins System
IBM Researchers Use Grocery Scanner Data to Speed Investigations During Early Foodborne Illness Outbreaks
DSM Informs Market of Final Pricing of Patheon N.V. IPO

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (